Table 1 Demographic characteristics of the eligible study population
Parameter | Number of patients ( N = 1,363) |
|---|---|
Age, years | |
18-34 | 26 (1.9%) |
35-54 | 357 (26.2%) |
55-74 | 724 (53.1%) |
≥75 | 256 (18.8%) |
Gender | |
Female | 640 (47.0%) |
Male | 723 (53.0%) |
Race | |
Caucasian | 724 (53.1%) |
African American | 182 (13.4%) |
Hispanic | 8 (0.6%) |
Other | 23 (1.7%) |
Not recorded | 426 (31.3%) |
Insurance type | |
Commercial | 663 (48.6%) |
Medicare | 461 (33.8%) |
Medicaid | 105 (7.7%) |
Self-pay | 83 (6.1%) |
Other | 51 (3.7%) |
Death reported | 653 (47.9%) |
Enrolled in a clinical trial | 151 (11.1%) |
Location of cancer | |
Colon | 915 (67.1%) |
Rectum | 397 (29.1%) |
Both | 51 (3.7%) |
Course of mCRC | |
Newly diagnosed | 482 (35.4%) |
Recurrent | 43 (3.2%) |
Other | 4 (0.3%) |
Not reported | 834 (61.2%) |
Consolidated/Combined ECOG/KPS score | |
ECOG = 0 to 1/KPS = 80 to 100 | 466 (34.2%) |
ECOG = 2-4/KPS = 10-70 | 274 (20.1%) |
Not reported | 623 (45.7%) |
Histologic grade | |
Well differentiated | 40 (2.9%) |
Moderately differentiated | 265 (19.4%) |
High grade/poorly differentiated | 89 (6.5%) |
Undifferentiated | 3 (0.2%) |
Cannot be assessed | 30 (2.2%) |
Not reported | 936 (68.7%) |
KRAS genotype | |
Wild-type | 312 (22.9%) |
Mutant | 274 (20.1%) |
Unknown | 62 (4.5%) |
Not tested | 715 (52.5%) |